In a controlled, randomized, multicenter, double-blind study involving 335 patients with generalized anxiety disorder, buspirone (Busp) was compared to Iorazepam, diazepam or bromazepam in order to test its global efficacy, preferential effectiveness in defined subgroups of patients or symptoms, latency of action and safety and tolerability. Apart from minor differences, the dropout rate, the number of subjects for whom the dose was increased, the number of capsules taken daily, the modifications of HRSA, VAS 100 mm, CGIS and CGSRS, the curves of improvement over time, the effectiveness on the somatic and psychic factors of the HRSA, the responsiveness of depressed and non-depressed anxious patients, and the profiles of adverse events indicated clinical equivalence between the azaspirodecanedione and the comparison benzodiazepines.

No abstract